Innate Pharma S.A.
IPHA | NASDAQ
$1.80
-$0.06 (-3.23%)
Sep 22, 2026, 12:31 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 2.79M | 12.62M | 51.9M | 57.67M | 12.11M | 69.77M |
Cost of Revenue | n/a | 51.98M | 56.02M | 51.66M | 47M | 49.71M |
Gross Profit | 2.79M | 12.62M | 5.62M | 6.01M | -22.3M | 20.07M |
Operating Income | -53.43M | -51.58M | -12.67M | -57.43M | -47.83M | 1.08M |
Interest Income | 1.32M | 2.44M | 3.18M | 546K | 327K | 564K |
Pretax Income | -49.18M | -49.47M | -7.57M | -57.97M | -45.48M | -829K |
Net Income | -49.18M | -49.47M | -7.57M | -58.1M | -52.81M | -63.98M |
Selling & General & Admin | 11M | 11.93M | 11.75M | 14.47M | 25.52M | 18.99M |
Research & Development | 43.62M | 51.98M | 56.02M | 51.66M | 47M | 49.71M |
Other Expenses | 1.59M | 283K | -49.48M | -2.7M | -47M | -49.71M |
Operating Expenses | 56.21M | 64.2M | 18.29M | 63.44M | 25.52M | 18.99M |
Interest Expense | 440K | 566K | 640K | 288K | 312K | 341K |
Selling & Marketing Expenses | n/a | 309K | 316K | 530K | 9.53M | 408K |
Cost & Expenses | 56.21M | 64.2M | 74.31M | 115.1M | 59.94M | 68.69M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 89.42M | 81.05M | 84.11M | 79.59M | 79.54M | 78.93M |
Shares Outstanding (Diluted) | 89.42M | 81.05M | 84.11M | 79.64M | 79.54M | 78.93M |
EPS (Basic) | -0.53 | -0.61 | -0.09 | -0.73 | -0.57 | -0.01 |
EPS (Diluted) | -0.53 | -0.61 | -0.09 | -0.73 | -0.57 | -0.01 |
EBITDA | -43.65M | -46.91M | -1.84M | -12.28M | -43.23M | 13.31M |
EBIT | -48.74M | -48.91M | -6.93M | -57.68M | -47.83M | 1.08M |
Depreciation & Amortization | 5.09M | 1.99M | 5.09M | 45.41M | 4.6M | 12.23M |
Add to Watchlist
Select watchlists to add or remove IPHA